Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kala Bio Inc (KALA)

Kala Bio Inc (KALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,637
  • Shares Outstanding, K 9,830
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,510 K
  • EBIT $ -38 M
  • EBITDA $ -37 M
  • 60-Month Beta -2.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.93
  • Most Recent Earnings $-1.07 on 11/19/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.74
  • Growth Rate Est. (year over year) +57,513.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6076 +11.13%
on 11/21/25
1.9100 -64.65%
on 12/01/25
-0.0513 (-7.06%)
since 11/12/25
3-Month
0.6076 +11.13%
on 11/21/25
20.6000 -96.72%
on 09/17/25
-17.9448 (-96.37%)
since 09/12/25
52-Week
0.6076 +11.13%
on 11/21/25
20.6000 -96.72%
on 09/17/25
-5.4148 (-88.91%)
since 12/12/24

Most Recent Stories

More News
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering...

KALA : 0.6752 (-2.82%)
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of...

KALA : 0.6752 (-2.82%)
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

ARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...

KALA : 0.6752 (-2.82%)
KALA BIO: Q3 Earnings Snapshot

KALA BIO: Q3 Earnings Snapshot

KALA : 0.6752 (-2.82%)
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related...

KALA : 0.6752 (-2.82%)
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...

KALA : 0.6752 (-2.82%)
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...

KALA : 0.6752 (-2.82%)
KALA BIO: Q2 Earnings Snapshot

KALA BIO: Q2 Earnings Snapshot

KALA : 0.6752 (-2.82%)
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9...

KALA : 0.6752 (-2.82%)
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...

KALA : 0.6752 (-2.82%)

Business Summary

KALA BIO is a clinical-stage biopharmaceutical company. It focused on the research, development and commercialization of therapies for rare and severe diseases of the eye. The company' s lead product candidate consists KPI-012. KALA BIO, formerly known as Kala Pharmaceuticals Inc., is based in ARLINGTON,...

See More

Key Turning Points

3rd Resistance Point 0.7665
2nd Resistance Point 0.7481
1st Resistance Point 0.7117
Last Price 0.6752
1st Support Level 0.6569
2nd Support Level 0.6385
3rd Support Level 0.6021

See More

52-Week High 20.6000
Fibonacci 61.8% 12.9629
Fibonacci 50% 10.6038
Fibonacci 38.2% 8.2447
Last Price 0.6752
52-Week Low 0.6076

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar